NEW YORK (GenomeWeb) – The Structural Genomics Consortium and the CHDI Foundation have struck an agreement to discover and characterize new drug targets for Huntington's disease and to make their findings available for use by academic researchers and pharmaceutical and biotechnology companies.

Neither the SGC nor CHDI will file for patents on any of their research findings, but will make all the reagents and knowledge they generate widely available without restrictions, the partners said yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.